{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:37:28Z","timestamp":1792787848262,"version":"4.5.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"name":"Chula Research Scholar, Ratchadaphiseksomphot Endowment Fund"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s12876-017-0696-4","type":"journal-article","created":{"date-parts":[[2017,12,7]],"date-time":"2017-12-07T20:12:55Z","timestamp":1512677575000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":116,"title":["Non-alcoholic fatty liver disease as a risk factor for cholangiocarcinoma: a systematic review and meta-analysis"],"prefix":"10.1186","volume":"17","author":[{"given":"Nicha","family":"Wongjarupong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Buravej","family":"Assavapongpaiboon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paweena","family":"Susantitaphong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wisit","family":"Cheungpasitporn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sombat","family":"Treeprasertsuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rungsun","family":"Rerknimitr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roongruedee","family":"Chaiteerakij","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,12,8]]},"reference":[{"key":"696_CR1","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nrgastro.2016.51","volume":"13","author":"JM Banales","year":"2016","unstructured":"Banales JM, Cardinale V, Carpino G, Marzioni M, Andersen JB, Invernizzi P, et al. Expert consensus document: cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European network for the study of cholangiocarcinoma (ENS-CCA). Nat Rev Gastroenterol Hepatol. 2016;13:261\u201380.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"696_CR2","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1245\/s10434-015-5046-6","volume":"23","author":"A Ruzzenente","year":"2016","unstructured":"Ruzzenente A, Fassan M, Conci S, Simbolo M, Lawlor RT, Pedrazzani C, et al. Cholangiocarcinoma heterogeneity revealed by multigene mutational profiling: clinical and prognostic relevance in surgically resected patients. Ann Surg Oncol. 2016;23:1699\u2013707.","journal-title":"Ann Surg Oncol"},{"key":"696_CR3","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.cld.2015.10.001","volume":"20","author":"M Sayiner","year":"2016","unstructured":"Sayiner M, Koenig A, Henry L, Younossi ZM. Epidemiology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis in the United States and the rest of the world. Clin Liver Dis. 2016;20:205\u201314.","journal-title":"Clin Liver Dis"},{"key":"696_CR4","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1007\/s00535-016-1264-3","volume":"52","author":"WK Seto","year":"2017","unstructured":"Seto WK, Yuen MF. Nonalcoholic fatty liver disease in Asia: emerging perspectives. J Gastroenterol. 2017;52:164\u201374.","journal-title":"J Gastroenterol"},{"key":"696_CR5","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1111\/j.1365-2036.2011.04724.x","volume":"34","author":"G Vernon","year":"2011","unstructured":"Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther. 2011;34:274\u201385.","journal-title":"Aliment Pharmacol Ther"},{"key":"696_CR6","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1002\/hep.28123","volume":"62","author":"ZM Younossi","year":"2015","unstructured":"Younossi ZM, Otgonsuren M, Henry L, Venkatesan C, Mishra A, Erario M, et al. Association of nonalcoholic fatty liver disease (NAFLD) with hepatocellular carcinoma (HCC) in the United States from 2004 to 2009. Hepatology (Baltimore, Md). 2015;62:1723\u201330.","journal-title":"Hepatology (Baltimore, Md)"},{"key":"696_CR7","doi-asserted-by":"crossref","first-page":"717","DOI":"10.3390\/ijms17050717","volume":"17","author":"C Sanna","year":"2016","unstructured":"Sanna C, Rosso C, Marietti M, Bugianesi E. Non-alcoholic fatty liver disease and extra-hepatic cancers. Int J Mol Sci. 2016;17:717.","journal-title":"Int J Mol Sci"},{"key":"696_CR8","first-page":"419A","volume":"96","author":"G Eng","year":"2016","unstructured":"Eng G, Zukerberg L, Deshpande V. The incidence of steatosis and steatohepatitis in intrahepatic cholangiocarcinoma and extrahepatic cholangiocarcinoma [Abstract]. Lab Investig. 2016;96:419A.","journal-title":"Lab Investig"},{"key":"696_CR9","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1002\/jso.24223","volume":"113","author":"M Kinoshita","year":"2016","unstructured":"Kinoshita M, Kubo S, Tanaka S, Takemura S, Nishioka T, Hamano G, et al. The association between non-alcoholic steatohepatitis and intrahepatic cholangiocarcinoma: a hospital based case-control study. J Surg Oncol. 2016;113:779\u201383.","journal-title":"J Surg Oncol"},{"key":"696_CR10","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1016\/j.cgh.2007.05.020","volume":"5","author":"TM Welzel","year":"2007","unstructured":"Welzel TM, Graubard BI, El-Serag HB, Shaib YH, Hsing AW, Davila JA, et al. Risk factors for intrahepatic and extrahepatic cholangiocarcinoma in the United States: a population-based case-control study. Clin Gastroenterol Hepatol. 2007;5:1221\u20138.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"696_CR11","doi-asserted-by":"crossref","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","volume":"6","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6:e1000097.","journal-title":"PLoS Med"},{"key":"696_CR12","unstructured":"Wells GA, Shea B, O'Connell D, Peterson J, Welch V, Losos M et al.. The Newcastle-Ottawa scale (NOS) for assessing the quality of nonrandomised studies in meta-analysis. 2011. [website]. http:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp . Available from: URL: http:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp . Accessed 1 Nov 2015."},{"key":"696_CR13","doi-asserted-by":"crossref","first-page":"e109733","DOI":"10.1371\/journal.pone.0109733","volume":"9","author":"Y Liu","year":"2014","unstructured":"Liu Y, He Y, Li T, Xie L, Wang J, Qin X, et al. Risk of primary liver cancer associated with gallstones and cholecystectomy: a meta-analysis. PLoS One. 2014;9:e109733.","journal-title":"PLoS One"},{"key":"696_CR14","doi-asserted-by":"crossref","unstructured":"Chaiteerakij R, Yang JD, Harmsen WS, Slettedahl SW, Mettler TA, Fredericksen ZS, et al. Risk factors for intrahepatic cholangiocarcinoma: Association between metformin use and reduced cancer risk. Hepatology. 2013;57:648\u201355.","DOI":"10.1002\/hep.26092"},{"key":"696_CR15","doi-asserted-by":"crossref","first-page":"6642","DOI":"10.18632\/oncotarget.14254","volume":"8","author":"YJ Huang","year":"2017","unstructured":"Huang YJ, ATH W, Chiou HY, Chuang MT, Meng TC, Chien LN, et al. Interactive role of diabetes mellitus and female sex in the risk of cholangiocarcinoma: a population-based nested case-control study. Oncotarget. 2017;8:6642\u201351.","journal-title":"Oncotarget"},{"key":"696_CR16","doi-asserted-by":"crossref","unstructured":"Choi J, Ghoz HM, Peeraphatdit T, Baichoo E, Addissie BD, Harmsen WS, et al. Aspirin use and the risk of cholangiocarcinoma. Hepatology. 2016;64:785\u201396.","DOI":"10.1002\/hep.28529"},{"key":"696_CR17","doi-asserted-by":"crossref","unstructured":"Chang JS, Tsai CR, Chen LT. Medical risk factors associated with cholangiocarcinoma in Taiwan: a population-based case-control study. PloS one. 2013;8:e69981.","DOI":"10.1371\/journal.pone.0069981"},{"key":"696_CR18","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1111\/liv.12618","volume":"35","author":"BS Lee","year":"2015","unstructured":"Lee BS, Cha BH, Park EC, Roh J. Risk factors for perihilar cholangiocarcinoma: a hospital-based case-control study. Liver Int. 2015;35:1048\u201353.","journal-title":"Liver Int"},{"key":"696_CR19","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.canep.2016.01.002","volume":"40","author":"M Stepien","year":"2016","unstructured":"Stepien M, Fedirko V, Duarte-Salles T, Ferrari P, Freisling H, Trepo E, et al. Prospective association of liver function biomarkers with development of hepatobiliary cancers. Cancer Epidemiol. 2016;40:179\u201387.","journal-title":"Cancer Epidemiol"},{"key":"696_CR20","first-page":"935","volume":"17","author":"HB Zhou","year":"2009","unstructured":"Zhou HB, QR X, Wang H, Zhou DX, Wang H, Wang Q, et al. Risk factors of intrahepatic cholangiocarcinoma: a case-control study. Zhonghua Gan Zang Bing Za Zhi. 2009;17:935\u20139.","journal-title":"Zhonghua Gan Zang Bing Za Zhi"},{"key":"696_CR21","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1007\/s10620-014-3051-4","volume":"59","author":"I Doycheva","year":"2014","unstructured":"Doycheva I, Cox K, Haseeb A, Adler DG. Prevalence and relevance of nonalcoholic fatty liver disease in patients with primary sclerosing cholangitis. Dig Dis Sci. 2014;59:1645\u20136.","journal-title":"Dig Dis Sci"},{"key":"696_CR22","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.jhep.2014.09.007","volume":"62","author":"C Raggi","year":"2015","unstructured":"Raggi C, Invernizzi P, Andersen JB. Impact of microenvironment and stem-like plasticity in cholangiocarcinoma: molecular networks and biological concepts. J Hepatol. 2015;62:198\u2013207.","journal-title":"J Hepatol"},{"key":"696_CR23","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1053\/j.gastro.2005.04.014","volume":"129","author":"LA Adams","year":"2010","unstructured":"Adams LA, Lymp JF, St. Sauver J, Sanderson SO, Lindor KD, Feldstein A, et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology. 2010;129:113\u201321.","journal-title":"Gastroenterology"},{"key":"696_CR24","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1111\/j.1572-0241.2007.01709.x","volume":"103","author":"C Carter-Kent","year":"2008","unstructured":"Carter-Kent C, Zein NN, Feldstein AE. Cytokines in the pathogenesis of fatty liver and disease progression to steatohepatitis: implications for treatment. Am J Gastroenterol. 2008;103:1036\u201342.","journal-title":"Am J Gastroenterol"},{"key":"696_CR25","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.3390\/cancers6031220","volume":"6","author":"I Okazaki","year":"2014","unstructured":"Okazaki I, Noro T, Tsutsui N, Yamanouchi E, Kuroda H, Nakano M, et al. Fibrogenesis and carcinogenesis in nonalcoholic steatohepatitis (NASH): involvement of matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinase (TIMPs). Cancers. 2014;6:1220\u201355.","journal-title":"Cancers"},{"key":"696_CR26","doi-asserted-by":"crossref","first-page":"10517","DOI":"10.1158\/0008-5472.CAN-06-2130","volume":"66","author":"H Wehbe","year":"2006","unstructured":"Wehbe H, Henson R, Meng F, Mize-Berge J, Patel T. Interleukin-6 contributes to growth in cholangiocarcinoma cells by aberrant promoter methylation and gene expression. Cancer Res. 2006;66:10517\u201324.","journal-title":"Cancer Res"},{"key":"696_CR27","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1053\/gast.2001.20875","volume":"120","author":"M Jaiswal","year":"2001","unstructured":"Jaiswal M, LaRusso NF, Shapiro RA, Billiar TR, Gores GJ. Nitric oxide-mediated inhibition of DNA repair potentiates oxidative DNA damage in cholangiocytes. Gastroenterology. 2001;120:190\u20139.","journal-title":"Gastroenterology"},{"key":"696_CR28","doi-asserted-by":"crossref","first-page":"G88","DOI":"10.1152\/ajpgi.00539.2003","volume":"287","author":"N Ishimura","year":"2004","unstructured":"Ishimura N, Bronk SF, Gores GJ. Inducible nitric oxide synthase upregulates cyclooxygenase-2 in mouse cholangiocytes promoting cell growth. Am J Physiol Gastrointest Liver Physiol. 2004;287:G88\u201395.","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"696_CR29","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1158\/0008-5472.CAN-13-1911","volume":"74","author":"RV Guest","year":"2014","unstructured":"Guest RV, Boulter L, Kendall TJ, Minnis-Lyons SE, Walker R, Wigmore SJ, et al. Cell lineage tracing reveals a biliary origin of intrahepatic cholangiocarcinoma. Cancer Res. 2014;74:1005\u201310.","journal-title":"Cancer Res"}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-017-0696-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,23]],"date-time":"2020-10-23T20:19:09Z","timestamp":1603484349000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcgastroenterol.biomedcentral.com\/articles\/10.1186\/s12876-017-0696-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["696"],"URL":"https:\/\/doi.org\/10.1186\/s12876-017-0696-4","relation":{},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,12]]},"article-number":"149"}}